Drug Discovery

Kairos Pharma signs deal for Celyn Therapeutics’ CL-273

Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment.

Sanofi receives CHMP recommendation for Dupixent approval in Europe

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union (EU) for paediatric patients with chronic spontaneous urticaria (CSU).

BioMarin receives FDA approval for Palynziq use in adolescents

BioMarin Pharmaceutical has received the US Food and Drug Administration (FDA) approval for its supplemental biologics licence application (sBLA) for Palynziq’s (pegvaliase-pqpz) use in adolescents aged 12 and above with phenylketonuria (PKU).

Asahi Kasei to acquire Aicuris Anti-infective Cures for $920.7m

Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m).

IQVIA to acquire Charles River drug discovery assets

IQVIA Holdings has signed an agreement to acquire selected discovery service assets from Charles River Laboratories, aiming to expand its end-to-end capabilities.

Novo Nordisk and Vivtex collaborate for oral medicines development

Novo Nordisk and Vivtex have entered a partnership focused on developing next-generation oral biologic therapies to treat obesity, diabetes and related comorbidities.

Slate Medicines raises $130m in funds to progress anti-PACAP treatments

Slate Medicines has secured a $130m Series A financing round aimed at advancing anti-pituitary adenylate cyclase-activating polypeptide (PACAP) migraine therapies.

FDA accepts Beren Therapeutics’ NDA for Niemann-Pick disease

Beren Therapeutics has received the US Food and Drug Administration (FDA) acceptance to review its New Drug Application (NDA) for adrabetadex, an investigational therapy targeting intracellular cholesterol trafficking for infantile-onset Niemann-Pick disease type C (NPC).

AbbVie announces $380m investment in North Chicago API facilities

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago site in Illinois, US.